Konstantinos Syrigos

13.7k total citations · 2 hit papers
176 papers, 4.2k citations indexed

About

Konstantinos Syrigos is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Konstantinos Syrigos has authored 176 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Oncology, 77 papers in Pulmonary and Respiratory Medicine and 32 papers in Molecular Biology. Recurrent topics in Konstantinos Syrigos's work include Lung Cancer Treatments and Mutations (41 papers), Lung Cancer Research Studies (24 papers) and Cancer Immunotherapy and Biomarkers (20 papers). Konstantinos Syrigos is often cited by papers focused on Lung Cancer Treatments and Mutations (41 papers), Lung Cancer Research Studies (24 papers) and Cancer Immunotherapy and Biomarkers (20 papers). Konstantinos Syrigos collaborates with scholars based in Greece, United States and United Kingdom. Konstantinos Syrigos's co-authors include Αναστάσιος Κόλλιας, Konstantinos G. Kyriakoulis, Vasiliki Michalaki, George S. Stergiou, Jonathan Waxman, P. Charles, Garyphallia Poulakou, Evangelos Dimakakos, Dimitra Grapsa and Kurt A. Schalper and has published in prestigious journals such as Nature Genetics, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Konstantinos Syrigos

171 papers receiving 4.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Thromboembolic risk and anticoagulant therapy in COVID‐19 patients: emerging evidence and call for action

2020 338 citations Αναστάσιος Κόλλιας, Konstantinos G. Kyriakoulis et al. profile →
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

2015 324 citations Enriqueta Felip, Konstantinos Syrigos et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Konstantinos Syrigos Greece	32	2.1k	1.4k	860	553	516	176	4.2k
Panagiotis Paliogiannis Italy	32	1.3k 0.6×	1.1k 0.8×	990 1.2×	455 0.8×	409 0.8×	179	3.9k
Joe‐Elie Salem France	39	2.3k 1.1×	844 0.6×	1.0k 1.2×	333 0.6×	552 1.1×	181	5.7k
Yaling Han China	37	915 0.4×	974 0.7×	2.0k 2.3×	636 1.2×	563 1.1×	511	7.7k
Florian Laenger Germany	17	875 0.4×	1.4k 1.0×	693 0.8×	2.6k 4.7×	480 0.9×	53	4.9k
Ioannis Ntanasis‐Stathopoulos Greece	35	2.0k 1.0×	376 0.3×	1.3k 1.6×	1.9k 3.5×	419 0.8×	268	5.9k
Navneet Singh India	30	1.3k 0.6×	2.0k 1.5×	963 1.1×	171 0.3×	262 0.5×	247	4.2k
Bridget A. Robinson New Zealand	37	2.0k 1.0×	697 0.5×	1.3k 1.6×	157 0.3×	439 0.9×	140	4.4k
Tadashi Mio Japan	33	1.7k 0.8×	1.9k 1.4×	653 0.8×	209 0.4×	423 0.8×	156	3.8k
Michel M. van den Heuvel Netherlands	37	1.9k 0.9×	2.2k 1.6×	921 1.1×	282 0.5×	835 1.6×	196	5.0k
Jerry L. Spivak United States	48	742 0.4×	502 0.4×	2.1k 2.4×	447 0.8×	713 1.4×	182	7.4k

Countries citing papers authored by Konstantinos Syrigos

Since Specialization

Citations

This map shows the geographic impact of Konstantinos Syrigos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Konstantinos Syrigos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Konstantinos Syrigos more than expected).

Fields of papers citing papers by Konstantinos Syrigos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Konstantinos Syrigos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Konstantinos Syrigos. The network helps show where Konstantinos Syrigos may publish in the future.

Co-authorship network of co-authors of Konstantinos Syrigos

This figure shows the co-authorship network connecting the top 25 collaborators of Konstantinos Syrigos. A scholar is included among the top collaborators of Konstantinos Syrigos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Konstantinos Syrigos. Konstantinos Syrigos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dingemans, Anne‐Marie C., Konstantinos Syrigos, Lorenzo Livi, et al.. (2025). Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial. Lung Cancer. 207. 108683–108683.

Papadopoulou, Anna, et al.. (2025). Soluble PD-L1 and Serum Vascular Endothelial Growth Factor-B May Independently Predict Prognosis in Patients with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab. Cancers. 17(3). 421–421. 1 indexed citations

Charpidou, Andriani, Grigoris Gerotziafas, Sanjay Popat, et al.. (2024). Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint Blockade. Cancers. 16(2). 450–450. 3 indexed citations

Dardavesis, Theodoros, et al.. (2024). Chatbots in Cancer Applications, Advantages and Disadvantages: All that Glitters Is Not Gold. Journal of Personalized Medicine. 14(8). 877–877. 11 indexed citations

Nicolatou‐Galitis, Ourania, Amanda Psyrri, Nikolaos Tsoukalas, et al.. (2023). Oral Toxicities in Cancer Patients, Who Receive Immunotherapy: A Case Series of 24 Patients. SHILAP Revista de lepidopterología. 3(1). 123–133. 2 indexed citations

Kyriakoulis, Konstantinos G., Evangelos Dimakakos, M. Catalano, et al.. (2022). Practical Recommendations for Optimal Thromboprophylaxis in Patients with COVID-19: A Consensus Statement Based on Available Clinical Trials. Journal of Clinical Medicine. 11(20). 5997–5997. 10 indexed citations

Dimakakos, Evangelos, Georgia Gomatou, M. Catalano, et al.. (2022). Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations–State-of-the-Art. Anticancer Research. 42(7). 3261–3274. 6 indexed citations

Κόλλιας, Αναστάσιος, et al.. (2021). Statin use and mortality in COVID-19 patients: Updated systematic review and meta-analysis. Atherosclerosis. 330. 114–121. 41 indexed citations

Κόλλιας, Αναστάσιος, Konstantinos G. Kyriakoulis, Ioannis P. Trontzas, et al.. (2021). High versus Standard Intensity of Thromboprophylaxis in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 10(23). 5549–5549. 11 indexed citations

10.

Magkrioti, Christiana, Nikos Oikonomou, Eleanna Kaffe, et al.. (2018). The Autotaxin—Lysophosphatidic Acid Axis Promotes Lung Carcinogenesis. Cancer Research. 78(13). 3634–3644. 48 indexed citations

11.

Corredor, Germán, Xiangxue Wang, Yu Zhou, et al.. (2018). Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non–Small Cell Lung Cancer. Clinical Cancer Research. 25(5). 1526–1534. 162 indexed citations

12.

Ali, Zaheer, Peter C. Sherrell, Georgios Lolas, et al.. (2018). Adjustable delivery of pro-angiogenic FGF-2 by collagen-alginate microspheres. Biology Open. 7(3). 20 indexed citations

13.

Altan, Mehmet, Vasiliki Pelekanou, Kurt A. Schalper, et al.. (2017). B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. Clinical Cancer Research. 23(17). 5202–5209. 108 indexed citations

14.

Villarroel‐Espíndola, Franz, Xiaoqing Yu, Ila Datar, et al.. (2017). Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer. Clinical Cancer Research. 24(7). 1562–1573. 162 indexed citations

15.

Nikolaou, Vasiliki, Andriani Charpidou, Ioanna Triantafyllopoulou, et al.. (2017). Anti-PD1/PDL1 induced psoriasis. Current Problems in Cancer. 41(6). 407–412. 84 indexed citations

16.

Tsiambas, Evangelos, Nicholas Mastronikolis, Stavros N Georgiannos, et al.. (2017). Chromosome 7 Multiplication in EGFR-positive Lung Carcinomas Based on Tissue Microarray Analysis. In Vivo. 31(4). 641–648. 9 indexed citations

17.

Toki, Maria, Franco Cecchi, Todd Hembrough, Konstantinos Syrigos, & David L. Rimm. (2016). PS01.30: Domain-Specific c-Met Measurement by Quantitative Immunofluorescence and Mass Spectrometry in Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 11(11). S287–S287. 1 indexed citations

18.

Kallianos, Anastasios, Aggeliki Rapti, Andriani Charpidou, et al.. (2012). AB 17. Cardiopulmonary exercise testing (CPET) as preoperative test before lung resection. Journal of Thoracic Disease. 4(1).

19.

Souglakos, John, Konstantinos Syrigos, Anna Potamianou, et al.. (2004). Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial. Annals of Oncology. 15(8). 1204–1209. 41 indexed citations

20.

Michalaki, Vasiliki, Konstantinos Syrigos, P. Charles, & Jonathan Waxman. (2004). Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer. British Journal of Cancer. 90(12). 2312–2316. 321 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact